Zydus and Bioeq Join Forces to Launch NUFYMCO® in the U.S. Market

Zydus Partners with Bioeq for U.S. Launch of NUFYMCO®

In a significant development for the biopharmaceutical industry, Zydus Lifesciences Limited, an innovative life sciences company, has entered a strategic partnership with Bioeq AG, a biopharmaceutical firm based in Switzerland. This collaboration focuses on the licensing, development, and commercialization of NUFYMCO®, an interchangeable biosimilar to the well-known drug Lucentis® (Ranibizumab), within the U.S. market.

On December 18, 2025, the U.S. Food and Drug Administration (FDA) approved NUFYMCO®’s Biologics License Application (BLA), heralding a new era of accessibility for patients requiring ophthalmological treatments. This announcement marks an exciting phase for Zydus, amplifying its presence in the U.S. biosimilar market. Not long ago, Zydus had also partnered with Formycon AG for a biosimilar version of another blockbuster drug, Keytruda® (Pembrolizumab).

Collaboration Details

Under this partnership, Bioeq will oversee various critical functions, including the development, manufacturing, registration, and supply of the finished NUFYMCO® product. Meanwhile, Zydus will harness its extensive commercial capabilities to introduce NUFYMCO® to the U.S. healthcare system. This divide of responsibilities is aimed at optimizing resource use and driving efficiency in bringing this important therapeutic option to market.

Dr. Sharvil P. Patel, the Managing Director of Zydus, expressed enthusiasm regarding this alliance. He emphasized the potential to leverage both companies' expertise and resources effectively: "Through this partnership, we will accelerate organizational growth while ensuring maximum value to patients through expanded access to affordable ophthalmology care."

Reflecting on the approval, Dr. Thiemo Schreiber, Vice President Commercial at Bioeq, stated, "The regulatory approval of NUFYMCO® as an interchangeable biosimilar of Lucentis® is an important milestone. Our collaboration with Zydus—whose distribution network and marketing strengths are well-established—will widen the treatment options available to patients. We aim to deliver high-quality, cost-effective therapies that enhance healthcare accessibility."

The Market Context

The biosimilar drug market is rapidly evolving, and the potential for NUFYMCO® is substantial. The total addressable market for biosimilar Ranibizumab in the U.S. is estimated to be around $210 million, as per IQVIA MAT data from September 2025. Given the increasing emphasis on affordable healthcare solutions, NUFYMCO® is poised to play a crucial role in the ophthalmic treatment landscape.

About Zydus Lifesciences

Zydus Lifesciences Limited prides itself on being an innovation-driven life sciences company with a vast portfolio that spans pharmaceuticals and consumer wellness products. With a global workforce exceeding 29,000, including around 1,500 scientists in research and development, the company is dedicated to transformative healthcare solutions. Zydus aims to create significant impact through groundbreaking discoveries.

About Bioeq AG

Established in 2014, Bioeq AG is a Swiss biopharmaceutical joint venture specializing in high-quality biosimilars targeted at regulated markets globally. The company's mission is to develop cost-effective alternatives to leading biologic medications. By collaborating with entities like Zydus, Bioeq strives to enhance patient accessibility to advanced therapeutic options.

This partnership between Zydus and Bioeq reinforces the potential for collaboration in the biopharmaceutical sector, offering hope for improved healthcare outcomes and increased access to vital treatments for patients in need.